APOE and coronary artery disorder: We have previously shown that we can slow the kinetics of fatality in SR-BI/apoE dKO mice by varying the timing of administration and/or withdrawal of probucol, a hypolipidemic and antioxidant drug that dramatically slows the onset and progression of CHD in these mice [2].